General Malaria Information

This information was provided by
The Malaria Research Programme of the Medical Research Council, South Africa

REFERENCES 1. Deacon HE, Freese JA, Sharp BL. 1994. Drug resistant falciparum malaria in the Eastern Transvaal. S Afr Med J. 84: 394-395. 2. Freese JA, Sharp BL, et al. 1994. The in vitro sensitivity of southern African isolates of Plasmodium falciparum to amodiaquine, chloroquine, mefloquine, quinine and sulfadoxine-pyrimethamine. S Afr J Sci. 90: 417-420. 3. Hansford CF. 1989. Chloroquine resistance in Plasmodium falciparum in KwaZulu 1983-1988. S Afr Med J. 76: 546-547. 4. Kruger P, Durrheim DN, Hansford CF. 1996. Increasing chloroquine resistance - the Mpumalanga lowveld story 1990-1995. S Afr Med J. 86: 281-282. 5. Department of Health. 1995. Malaria: revised prophylaxis policy. S Afr Med J. 85: 126-127. 6. Warrell DA, Molyneux ME, Beales PF. 1990. Severe and complicated malaria. World Health Organization Division of Control of Tropical Diseases. Second edition. London: Royal Society of Tropical Medicine and Hygiene. 7. Gilles HM. 1991. Management of severe and complicated malaria. A practical handbook. Geneva: World Health Organization. 8. Beadle C, Long GW, Weiss WR, et al. 1994. Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet. 343: 564-567. 9. Abramowicz M. 1992. Drugs for parasitic infections. Medical Letter. 34(865): 17-24. 10. Department of National Health and Population Development. 1994. Malaria in South Africa 1984-1993. Epidemiological Comments. 21(6): 110-117. 11. Luzzi GA, Peto TEA. 1993. Adverse effects of antimalarials: An update. Drug Safety. 8(4): 295-311. 12. Gelman CR, Rumack BH. 1995. DRUGDEX(R) Information System. Denver, Colorado: MICROMEDEX, Inc. 83.3. 13. World Health Organization. 1995. International travel and health guide: vaccination requirements and health advice. Geneva: World Health Organization. 14. Beards SC, Joynt GM, Lipman J. 1994. Haemodynamic and oxygen transport response during exchange transfusion for severe falciparum malaria. Postgraduate Med J. 70: 801-804. 15. World Health Organization. 1990. Model prescribing information. Drugs used in parasitic diseases. Geneva: World Health Organization: 41. 16. Nosten F, Price RN. 1995. New antimalarials: A risk-benefit analysis. Drug Safety. 12(4): 264-273. 17. Nosten F, Ter Kuile FO, et al. 1993. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 341: 1054-1056. 18. World Health Organization. 1993. Artemisinin and its derivatives: use as antimalarials. WHO Drug Information. 7(3): 111-113. 19. Artemisinin. 1994. Proceedings of a meeting convened by the Wellcome Trust. Transactions of the Royal Society of Tropical Medicine and Hygiene. 88 (Supplement 1): S1-65. 20. Report of a WHO Scientific Group. 1990. Practical chemotherapy of malaria. World Health Organization Technical Report Series 805. Geneva: World Health Organization. 21. Zeneca. 1995. Primaquine phosphate tablets. Package insert. 13 October 1995. 22. Bruce-Chwatt LJ, Black RH, Canfield CJ, et al. 1986. Chemotherapy of Malaria. Revised second edition. Geneva: World Health Organization. 23. Subramanian D, Moise KJ, White AC. 1992. Imported malaria in pregnancy: Report of four cases and review of management. Clin Inf Dis. 15: 408-13. 24. Vanhauwere B. 1995. Mefloquine. Post Marketing Surveillance of Lariam in Pregnancy. F. Hoffman - La Roche, Basel, Switzerland. Fourth International Conference on Travel Medicine, Mexico, April 23-27 1995. 25. Chongsuphajaisiddhi T. 1988. Malaria in paediatric practice. In: Wernsdorfer McGregor eds. Malaria: principles and practice of malariology. Edinburgh: Churchill Livingstone: 889-912. 26. Schlagenhauf P, Steffen R. 1994. Stand-by treatment of malaria in travellers: a review. J Trop Med Hyg. 97: 151-160.